Lead Product(s) : Xevinapant,Cisplatin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Merck Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer
Details : Debio 1143 (xevinapant) is an investigational potent oral small-molecule IAP inhibitor. It is being evaluated for the treatment of locally advanced squamous cell carcinoma of the head and neck.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 24, 2024
Lead Product(s) : Xevinapant,Cisplatin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Xevinapant
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : EMD Serono
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 17, 2024
Lead Product(s) : Xevinapant
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : EMD Serono
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Xevinapant
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : EMD Serono
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 31, 2023
Lead Product(s) : Xevinapant
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : EMD Serono
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Xevinapant
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 28, 2023
Lead Product(s) : Xevinapant
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Xevinapant
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 05, 2023
Lead Product(s) : Xevinapant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Xevinapant
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 13, 2023
Lead Product(s) : Xevinapant
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Xevinapant
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
PK Study of Xevinapant (Debio 1143) in Healthy East Asian Participants
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 29, 2022
Lead Product(s) : Xevinapant
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Xevinapant
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Xevinapant (formerly known as Debio 1143) is an investigational first-in-class potent oral small-molecule IAP (inhibitor of apoptosis protein) inhibitor for the treatment of LA SCCHN.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 09, 2022
Lead Product(s) : Xevinapant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Xevinapant
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 23, 2022
Lead Product(s) : Xevinapant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Xevinapant
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 15, 2021
Lead Product(s) : Xevinapant
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable